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Rationale and objective: Receptor-targeted delivery of imaging and therapeutic agents 
can lead to enhanced efficacy for both. Multimodality imaging offers unique advantages over 
traditional single modality imaging. Tumor marker folate receptor (FR)-targeted fluorescent 
paramagnetic bimodal liposomes were synthesized to co-deliver paramagnetic and fluorescence 
agents for magnetic resonance (MR) and optical bimodal imaging contrast enhancement.
Materials and methods: Fluorescent and paramagnetic bimodal liposomes were syn-
thesized with a mean diameter of 136 nm and a low polydispersity index. The liposomes 
incorporated folate-PEG3350-CHEMS for FR targeting, Gd(III)[N,N-Bis-stearylamidomethyl-
N’-amidomethyl]diethylenetriamine tetraacetic acid (Gd-DTPA-BSA) for MR contrast, 
and calcein for fluorescence. To determine the specificity and efficiency of delivery, the 
liposomes were evaluated in FR-positive KB and HeLa cells and FR-negative A549 cells, 
which were analyzed by fluorescence microscopy, magnetic resonance imaging (MRI), and 
flow cytometry (FCM).
Results: FR-specific and efficient cellular uptake of the FR-targeted bimodal liposomes was 
confirmed by fluorescence microscopy and by FCM. The mean fluorescence intensity (MFI) of 
KB cells treated with FR-targeted liposomes was 45× that of cells treated with nontargeted lipo-
somes, and 18× that of cells treated with FR-targeted liposomes and excess folic acid (FA). The 
MFI of HeLa cells treated with targeted liposomes was 33× that of nontargeted liposomes, and 
was 16× that of the mixture of targeted liposomes and free FA. In contrast, the MFI of A549 cells 
treated with FR-targeted liposomes was nearly the same as those treated with nontargeted 
liposomes. The T1-weighted MR images of HeLa and KB cells incubated with FR-targeted 
liposomes had much higher signal intensity than those treated with nontargeted liposomes or 
free Gd-DTPA. Furthermore, the FR-targeting effect could be blocked by excess free FA.
Conclusion: FR-targeted fluorescent paramagnetic bimodal liposomes provided a novel 
platform for bimodal tumor imaging and theranostic delivery.
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Introduction
Noninvasive diagnostic imaging techniques such as magnetic resonance imaging (MRI) 
and optical tomography are becoming increasingly important in cancer diagnosis and 
therapy. Imaging contrast agents can facilitate tumor detection at tissue, cellular and 
molecular levels.1 MRI enables the visualization of the three-dimensional structure 
of tissues. It has a high degree of spatial resolution but suffers from a relatively low 
sensitivity. Contrast agents can offer useful signal enhancement to MRI.2 Gadolinium-
diethylenetriamine pentaacetic acid/dimeglumine (Gd-DTPA/dimeglumine) 
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(Magnevist®, Bayer HealthCare, Leverkusen, Germany) is the 
first US Food and Drug Authority–approved clinical contrast 
agent. It is a low molecular weight compound without 
tissue specificity that is cleared rapidly from the circulation. 
Several contrast agents have been developed to prolong the 
circulation time and improve the tissue specificity of the 
magnetic resonance (MR) contrast agent.3–6 For example, 
Gd(III) [N,N-Bis-stearylamidomethyl-N′-amidomethyl]
diethylenetriamine tetraacetic acid (Gd-DTPA-BSA), 
an amphipathic Gd complex, has been synthesized for 
incorporation into liposomes.7 The resulting paramagnetic 
liposomes effectively enhanced T1-imaging. Optical imaging 
is another useful technology platform. Fluorescent probes 
can be used as optical contrast agents. However, optical 
imaging is hampered by the very limited depth of light 
penetration.8 Combining MRI and fluorescence imaging 
would enable visualization of tumors by MRI and analysis of 
histological samples by fluorescence imaging.9,10 In addition, 
Kircher et al reported the delineation of tumors both by 
preoperative MRI and by intraoperative optical imaging.11
Lipid-based nanoparticles, such as liposomes, micelles, 
and microemulsions, have been evaluated as carriers of MRI 
contrast and fluorescent agents for noninvasive imaging.9,12–20 
There are several recent reviews on lipid-based paramagnetic 
nanoparticles21,22 and on paramagnetic and fluorescent 
nanoparticles.3,10,23,24 Kostarelos and Miller described a 
modular design for targeted paramagnetic liposomes carrying 
nucleic acids, termed Gd-ABCD.25 These are Gd liposomes, 
in which “A” is condensed nucleic acids. “B” is a lipid bilayer, 
“C” is the PEG polymer, and “D” is a suitable ligand.25
Folate receptor (FR) is a well-known tumor marker. 
It has limited expression in normal tissues, and is greatly 
overexpressed in a variety of carcinomas.26 Folate conjugates 
of imaging agents have high binding affinity for cell-
surface FRs, which allows for selective targeting of tumor 
cells.27 Kamaly et al showed that FR-targeted fluorescent 
paramagnetic bimodal liposomes have increased accumulation 
in a FR + murine tumor model.13
In this study, the authors report the synthesis and 
evaluation of FR-targeting bimodal liposomes for MRI 
and fluorescent imaging based on the previously reported 
Gd-ABCD design.25 Gd-DTPA-BSA was incorporated 
into the bilayer of the liposomes as a paramagnetic agent, 
whereas calcein, a fluorescent dye, was encapsulated in the 
aqueous core of liposomes. Folate-polyethylene glycol3350-
cholesteryl hemisuccinate (folate-PEG3350-CHEMS)28 was 
used as a ligand for FR targeting. FR-mediated tumor cell 
targeting by these bimodal liposomes was demonstrated both 
by fluorescence imaging and MRI.
Materials and methods
Materials
Hydrogenated soy phosphatidylcholine (HSPC) and 
monomethoxy polyethylene glycol2000-distearoylphosphat-
idylethanolamine (mPEG2000-DSPE) were purchased from 
Avanti Polar Lipids Inc (Alabaster, AL). Cholesterol and 
octadecylamine were obtained from J&K Chemical Ltd 
(Beijing, China). Sepharose CL-4B chromatography media 
was purchased from Sigma Aldrich (St Louis, MO). Folic 
acid was purchased from Huixing Biological and Chemical 
Reagents Co, Ltd (Shanghai, China). Gadolinium oxide 
was purchased from Sinopharm Chemical Reagent Co, 
Ltd (Shanghai, China). Diethylenetriaminepentaacetic acid 
(DTPA) was purchased from Tianjin Yuanhang Chemical 
Reagents Co, Ltd (Tianjin, China). Calcein was purchased 
from Aladdin Reagent Co (Shanghai, China). Folate-PEG3350-
CHEM was synthesized in the authors’ laboratory, as 
described previously.28  All reagents were of analytical grade 
and were used without any further purification.
L-glutamine, trypsin (1:250), and EDTA-Na2 were 
  purchased from Amresco (Solon, OH). Penicillin-streptomycin 
(100,000 units/mL) was supplied by Hyclone (Logan, UT). 
Fetal bovine serum (FBS) was a product of Hangzhou 
Sijiqing Biological Engineering Materials Co, Ltd (Hang-
zhou, China). Roswell Park Memorial Institute medium 
(RPMI)–1640 10× medium without folic acid was purchased 
from Sigma Aldrich.
The human nasopharyngeal epidermal carcinoma KB 
cell line, which has been identified as being derived from the 
human cervical cancer HeLa cell line, was obtained from the 
Cell Bank at the Chinese Academy of Science (Shanghai, 
China). The human cervical carcinoma HeLa cell line was 
provided by the Tongji Hospital, Tongji Medical College, 
Huazhong University of Science and Technology, Hubei, 
China. A549, a human lung carcinoma cell line, was provided 
by the Union Hospital, Tongji Medical College.
Synthesis of Gd-DTPA-BSA
[N,N-Bis-stearylamidomethyl-N′-amidomethyl]diethylen-
etriamine tetraacetic acid (DTPA-BSA) was prepared using 
the method outlined by Kamaly et al.14 Briefly, a solution 
of octadecylamine dissolved in chloroform was added to 
a solution of DTPA bis-anhydride previously dissolved 
in dimethylformamide. The reaction was stirred at 40°C 
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for 2 hours. The white precipitate formed was collected 
by filtration and dried under vacuum overnight. The white 
solid was stirred in water to dissolve any excess DTPA 
and stirred in boiling chloroform to dissolve any excess 
DTPA bis-anhydride and octadecylamine. Gd3+ was then 
added to synthesize Gd-DTPA-BSA according to the pro-
cedure of Kabalka et al.7 The concentrations of Gd were 
determined by inductively coupled plasma atomic emission 
spectroscopy (ICP-AES) (OPTIMA 4300DV, Perkin Elmer 
Ltd, Waltham, MA). The phase-transition temperature 
of Gd-DTPA-BSA was determined by differential scan-
ning calorimetry on a Diamond DSC (Perkin Elmer Ltd, 
Waltham, MA).
Bimodal liposome preparation
The FR-targeted liposomes were prepared by hydration 
of a thin lipid film composed of HSPC/mPEG2000-DSPE/
cholesterol/Gd-DTPA-BSA/ folate-PEG3350-CHEMS at 
30/40/25/4/1 (mole/mole). Nontargeted liposomes composed 
of HSPC/mPEG2000-DSPE/Cholesterol/Gd-DTPA-BSA 
30/40/25/5 (mole/mole) were synthesized by the same 
method. Briefly, the lipids (0.05 mmol total) were dissolved 
in chloroform/methanol (1/1), followed by evaporation to 
dryness to form a lipid film. The lipid film was subsequently 
hydrated in 2 mL 2.5 mM calcein solution for 40 minutes at 
60°C and then sonicated for 10 minutes. The resulting lipid 
dispersion was extruded sequentially five times through 
polycarbonate membrane filters with a pore diameter of 
200 nm and 100 nm (Lipex Extruder, Northern Lipids Inc, 
Vancouver, Canada). Liposomes and free calcein were 
separated by size exclusion chromatography on a Sepharose 
CL-4B gel (Sigma Aldrich).
The size and zeta potential of the liposomes were 
determined by dynamic light scattering on a Zetasizer 
(nanoseries) Nano-ZS 90 (Malvern Instruments Ltd, 
Malvern, Worcestershire, UK). Fluorescence measurements 
were carried out on a fluorescence spectrophotometer 
(LS55 fluorescence spectrophotometer, Perkin Elmer Ltd). 
The incorporation of Gd in the liposome preparations was 
confirmed by ICP-AES. For MR imaging, nontargeted 
liposomes  (L-Gd/calcein),  FR-targeted  liposomes 
(F-L-Gd/calcein), and Gd-DTPA were prepared at three 
different concentrations. The MR images of liposome 
suspensions were collected, along with the MR image 
of water. The T1-weighted image was acquired by 3.0T 
MRI on a Signa HDxt Hdi 3.0T MRI (General Electric, 
Fairfield, CT).
In vitro targeting experiments
Fluorescence imaging of cells
KB cells were plated in a six-well plate at 37°C under 5% 
CO2 in folate-free RPMI 1640 medium containing 10% fetal 
bovine serum. The cells were grown until 80% confluence 
was reached. The medium was then removed and replaced 
with fresh medium (without serum). F-L-Gd/calcein, L-Gd/
calcein, and F-L-Gd/calcein plus 1 mM folic acid (FA) were 
added. FA was added to FR-targeted liposomes prior to use 
in cellular treatment. All liposomes contained calcein at a 
concentration of 15.2 µM. One mM FA was used as an FR 
blocking agent. After incubation at 37°C for 1 hour, the cells 
were examined on an Olympus IX71 fluorescence micro-
scope (Perkin Elmer Ltd).
Quantitative analysis of cell uptake
KB, HeLa, and A549 cells were seeded into six-well plates 
and separately incubated with F-L-Gd/calcein, L-Gd/calcein, 
and F-L-Gd/calcein plus 1 mM FA. The final concentration 
of calcein in the incubation media was 12µM. After incuba-
tion at 37°C for 1 hour, the cells were washed 3× with cold 
phosphate-buffered saline (PBS) and treated with trypsin. 
The fluorescence intensity of cells was analyzed by flow 
cytometry (FCM) on a BD-LSR cytometer (BD Biosciences, 
Franklin Lakes, NJ). Each study was repeated 3–4 times.
MR imaging of cells
HeLa and KB cells were grown in folate-free RPMI 
1640 medium containing 10% fetal bovine serum. The cells 
were grown to 80% confluence and were then suspended by 
treatment with trypsin. Aliquots of the cells were transferred 
to Eppendorf tubes and were incubated with fresh media 
containing FR-targeted or nontargeted liposomes. The final 
concentration of Gd in the incubation media was 18.5 mg/L. 
After incubation at 37°C for 1 hour, cells were washed 3× with 
cold PBS. The tubes were imaged on a 3.0T MRI with a 
standard spin-echo sequence (time of repetition = 20, 40, 100, 
200 ms; time of echo = 9.0 ms/Fr; number of excitation: 2.0).
Results
Synthesis of Gd-DTPA-BSA
The identity of Gd-DTPA-BSA product was confirmed by its 
melting point and IR spectrum (data not shown). Based on ICP-
AES determination, the complex   contained 13.3% Gd. The 
phase-transition temperature of Gd-DTPA-BSA was found 
to be 65.32°C.
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Characterization of the bimodal 
liposomes
Size and zeta potential of the liposomes
Liposomes had a mean diameter of ∼136 nm with a low 
polydispersity index. The preparations were stable for at least 
3 months at 4°C (Figure 1A). The zeta potential of liposomes 
was ∼-13.6 mV (Figure 1B).
The incorporation of calcein and Gd
The maximum fluorescence emission wavelength of   calcein 
did not change when being encapsulated in liposomes 
(Ex-max was at 491 nm, Em-max was at 511 nm). The 
encapsulation efficiency for calcein was low, ranging from 
1.2% to 4.7%, as determined by UV absorption at 491 nm. 
Meanwhile, the encapsulation efficiency for Gd was sub-
stantially higher, ranging from 20% to 27%, as determined 
by ICP-AES.
MR imaging of liposomes
Compared with water, the Gd liposomes and Gd-DTPA 
all showed brighter MR signals in T1-weighted images 
 ( Figure 2). Therefore, the paramagnetic liposomes were 
demonstrated to be MR detectable. The intensity of the signal 
was concentration dependent. A decrease in the concentra-
tion of the Gd liposomes was associated with a reduction in 
signal intensity in the MR image (Figure 2). The MR images 
of Gd-DTPA were slightly brighter than those of liposomes. 
This might be due to easier proton exchange between the 
bulk water and the Gd-DTPA.
In vitro targeting experiments
Fluorescence imaging of cells
Uptake of liposomes by FR positive KB cells was analyzed 
by fluorescence microscopy. Green fluorescence was 
associated with liposomal calcein. As shown in Figure 3, 
F-L-Gd/calcein (Figure 3B and Figure 3B′) was taken up 
by the KB cells more efficiently than nontargeted liposomes 
(Figure 3A and Figure 3A′), and the uptake could be blocked 
by 1 mM free FA (Figure 3C and Figure 3C′). Addition-
ally, FR-targeted liposomes were primarily located on the 
surface of cell membrane. This phenomenon was consistent 
with previous observations,29,30 which showed extensive 
surface binding of FR-targeted liposomes to the FR on the 
cell surface.
Quantitative analysis of cell uptake
Targeted and nontargeted liposomes were incubated with 
FR positive tumor cells (KB and HeLa) and FR negative 
tumor cells (A549). Free FA, used as a blocking agent, 
was added to FR-targeted liposomes prior to use in cel-
lular   treatment. The FR specificity of cellular uptake of 
targeted and nontargeted liposomes was quantitatively 
analyzed by FCM. The experiments were repeated at least 
three times. (Table 1, Figure 4). The MFI of KB cells 
treated with F-L-Gd/calcein was 45 times higher than 
that of cells treated with nontargeted L-Gd/calcein, and 
18 times higher than that of cells treated with the F-L-Gd/
calcein plus 1 mM free FA. The MFI of HeLa cells treated 
with F-L-Gd/calcein was 33 times higher than that of cells 
treated with nontargeted liposomes L-Gd/calcein, and 16 
times higher than that of cells treated with the F-L-Gd/cal-
cein plus 1 mM free FA. In contrast, the MFI of A549 cells 
treated with F-L-Gd/calcein was nearly identical with that 
of cells treated with L-Gd/calcein, or F-L-Gd/calcein plus 
free FA. In summary, the FR-targeted liposomes F-L-Gd/
calcein showed delivery specificity in FR positive cells but 
not in FR negative cells, and the FR targeting effect could 
be blocked by 1 mM free FA.
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Figure 1 Size (A) and zeta potential (B) distribution of the FR-targeted liposomes (F-L-Gd/calcein). The mean diameter of the liposomes was 136 nm (A), and the zeta 
potential was about -13.6 mV (B).
Abbreviation: FR, folate receptor.
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L-Gd/calcein
F-L-Gd/calcein
Gd-DTPA
Conc. of Gd 2.2 mmol.L-1 1.1 mmol.L-1 0.5 mmol.L-1
Conc. of Gd 2.2 mmol.L-1 1.1 mmol.L-1 0.5 mmol.L-1
Conc. of Gd 2.2 mmol.L-1 1.1 mmol.L-1 0.5 mmol.L-1 Control:
Water
Figure 2 T1-weighted images of Gd-liposomes and Gd-DTPA.
Abbreviations: DTPA, diethylenetriamine pentaacetic acid; Conc., concentration.
A
AB C
BC
Figure 3 Uptake of liposomal calcein by KB cells. The cells were incubated at 37°C for 1 hour with L-Gd/calcein (A, A′), F-L-Gd/calcein (B, B′), or F-L-Gd/calcein + 1 mM 
FA (C, C′). Top panels show cells visualized in the phase-contrast mode (A, B, C); bottom panels show the same fields in the fluorescence mode (A′, B′, C′)
Abbreviation: FA, folic acid.
MRI of cells
For MRI, HeLa cells were incubated with (1) blank 
liposome, (2) L-Gd/calcein, (3) F-L-Gd/calcein, (4) F-L-Gd/
calcein + 1 mM FA, or (5) Gd-DTPA for 1 hour. From 
T1-weighted images, the tube containing HeLa cells incubated 
with F-L-Gd/calcein (Figure 5C) had a much higher signal 
intensity than that of the tubes of cells treated with blank 
liposomes or nontargeted liposomes (Figure 5A and 5B). This 
was probably due to FR-mediated uptake by the FR-positive 
HeLa cells. The MR signal was diminished when the cells 
were incubated with F-L-Gd/calcein + 1 mM FA. This showed 
the blocking of FR-dependent uptake by free FA (Figure 5D). 
The MR image of HeLa cells incubated with F-L-Gd/calcein 
was also brighter than that of HeLa cells incubated with Gd-
DTPA (Figure 5E). This may be due to the fact that Gd-DTPA 
was unable to enter cells by diffusion due to its hydrophilicity 
and was therefore removed during washing of the cells. 
Meanwhile, the liposomes were retained on the cell surface 
via FR binding and therefore enhanced the T1 signal.
KB cells were also incubated with (1) L-Gd/calcein, 
(2) F-L-Gd/calcein, or (3) F-L-Gd/calcein + 1 mM FA for 
1 hour at 37°C followed by washing with PBS. MRI showed 
that cells incubated with F-L-Gd/calcein had the highest 
signal intensity (Figure 6B), and that this could be blocked 
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by 1 mM free FA (Figure 6C). These data further confirmed 
FR-dependent cellular uptake of F-L-Gd/calcein in another 
FR-positive cell line.
Discussion
Liposomes are long-circulating vehicles that are capable 
of encapsulation of water-soluble agents and incorporation 
of amphiphilic and hydrophobic agents in the lipid bilayer. 
Two types of liposomal MRI contrast agents have been 
described.22,23 The first is based on liposomes entrapping 
paramagnetic agents, typically Gd-DTPA, in the aqueous 
lumen.31,32 A drawback of these liposomes is that encapsula-
tion reduces the relaxivity of the paramagnetic agent, because 
of the limited access to exchange with bulk water by the 
contrast agents. A second type of liposomal contrast agents 
are based on liposomes carrying amphiphilic paramagnetic 
molecules in the lipid bilayer, which makes them an integral 
part of the liposomal surface, therefore providing greater 
access to proton exchange with water compared with the 
liposomes of the first type. Lipid chain length and degree 
of saturation affect the particle relaxivity of the second type 
of liposomes.33
In this study, a combination of an amphiphilic Gd-
DTPA-BSA and a fluorescent dye, calcein, was used to 
prepare fluorescent paramagnetic bimodal liposomes. 
Gd-DTPA-BSA has been used in previous studies.9,19 The 
amount of Gd-DTPA-BSA used in this study, which was 
25 mole % of total lipids (50 µmol), was consistent with 
previous reports.9 Calcein is a hydrophilic fluorescent 
marker that has been used to investigate membrane 
  permeability.9 Calcein can be replaced by quantum dots, 
other fluorescent probes, or a hydrophilic therapeutic drug 
in further work. Effective FR targeting was achieved by 
incorporation of folate-PEG3350-CHEM at 1 mole% of the 
total lipids.
The small size, the slightly negative zeta potential of 
the liposomes (Figure 1), along with surface PEGylation 
are expected to produce a relatively long circulation time 
in vivo.21,34 The liposomes were shown to be paramagnetic 
(Figure 2). When the concentration of the contrast agents 
decreased, the contrast of MR images was also decreased. 
The T1 image intensity of Gd-liposomes and Gd-DTPA 
were much higher than that of water. In   addition, the 
T1 images of Gd-DTPA were slightly brighter than those 
of Gd-liposomes at the same Gd concentration, pre-
sumably due to greater access to proton exchange with 
environmental water.
The uptake of F-L-Gd/calcein by KB and HeLa cells 
was FR specific, which was also confirmed qualitatively 
by fluorescence microscopy (Figure 3) and MRI   (Figure 5, 
Figure 6), and then quantitatively by FCM (Table 1, Figure 4). 
FR-targeted liposomes were primarily located on the surface 
Figure 5 T1-weighted image of HeLa cells after incubated with contrast agents (coronal 
scan). (A) L. (B) L-Gd/calcein. (C) F-L-Gd/calcein. (D) F-L-Gd/calcein + 1 mM FA. 
(E)   Gd-DTPA.
Abbreviations: FA, folic acid; DTPA, diethylenetriamine pentaacetic acid.
Figure  6  T1-weighted  image  of  KB  cells  after  incubated  with  contrast  agents 
(I, coronal scan; II, axial scan) (A) L-Gd/calcein. (B) F-L-Gd/calcein. (C) F-L-Gd/
calcein + 1 mM FA.
Abbreviation: FA, folic acid.
Table 1 Uptake of liposomal calcein by KB, HeLa, and A549 cells 
determined by flow cytometry
L-Gd/calcein F-L-Gd/calcein F-L-Gd/calcein + FA
KB 491 ± 236 22,334 ± 8451 1269 ± 395
HeLa   96 ± 20    3181 ± 400   203 ± 120
A549 110 ± 22    138 ± 82   151 ± 104
Abbreviation: FA, folic acid.
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Figure 4 Comparison of the uptake of liposomes between FR-positive (KB, HeLa) 
and FR-negative (A549) cell lines.
Abbreviations: FR, folate receptor; FA, folic acid.
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of the cell membrane (Figure 3), due to binding to FR. Uptake 
of the liposomes was greater in KB cells than in HeLa cells. 
This can be explained by the higher FR expression in the 
former.35
Conclusion
FR-targeted fluorescent paramagnetic bimodal liposomes 
were synthesized. Both MRI and fluorescence imaging 
showed FR-specific uptake of these liposomes in FR-positive 
but not FR-negative cells. Further work will determine 
the plasma clearance kinetics and the biodistribution of 
the liposomes in vivo. In addition, the authors will explore 
loading the liposomes with therapeutic agents to enable 
image-guided therapy.
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